Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents.

Trial Profile

Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2014

At a glance

  • Drugs Everolimus (Primary) ; Umirolimus (Primary)
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms BESS
  • Most Recent Events

    • 11 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Jul 2012 According to ClinicalTrials.gov record, sirolimus-eluting stent treatment arm has been deleted. Now the trial consists of only 2 arms- biolimus-eluting and everolimus-eluting stent.
    • 20 Jul 2012 Planned number of patients changed from 3000 to 1462 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top